UOC
AVEO

UBS O'Connor’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

UBS O'Connor’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-49,360
Closed -$291K – 520
2017
Q1 		$291K Buy
+49,360
New +$357K ﹤0.01% 369

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS O'Connor's AVEO Position: Q2 2017 in Review

UBS O'Connor sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2017, closing a stake of 49,360 shares — an estimated $291K sold.

UBS O'Connor first reported a position in AVEO in Q1 2017 and held it in 1 quarter. The position peaked at $291K in Q1 2017. 49 funds tracked by Wall St. Rank hold AVEO as of Q2 2017.

  • UBS O'Connor reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • UBS O'Connor sold 49,360 AVEO Pharmaceuticals, Inc. shares in Q2 2017, an estimated $291K.
  • UBS O'Connor first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • UBS O'Connor's AVEO Pharmaceuticals, Inc. position peaked at $291K in Q1 2017.
  • 49 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2017.

Based on UBS O'Connor's 13F filing for Q2 2017, filed 14 Aug 2017.